(Q43040791)

12 November 2017

title

Pharmacokinetics of mycophenolic acid in severe lupus nephritis (English)

1 reference

12 November 2017

1 reference

Paungpaga Lertdumrongluk

1

1 reference

12 November 2017

Poorichaya Somparn

2

1 reference

12 November 2017

Wonngarm Kittanamongkolchai

3

1 reference

12 November 2017

Opas Traitanon

4

1 reference

12 November 2017

Somratai Vadcharavivad

5

1 reference

12 November 2017

Yingyos Avihingsanon

6

1 reference

12 November 2017

language of work or name

English

0 references

publication date

9 June 2010

1 reference

12 November 2017

1 reference

12 November 2017

volume

78

1 reference

12 November 2017

issue

4

1 reference

12 November 2017

page(s)

389-395

1 reference

Lupus Nephritis in Thailand: Clinicopathologic findings and outcome in 569 patients

12 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.170

7 January 2021

Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.170

7 January 2021

Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.170

7 January 2021

Quality of life comparison between corticosteroid- and-mycofenolate mofetil and corticosteroid- and-oral cyclophosphamide in the treatment of severe lupus nephritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.170

7 January 2021

Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.170

7 January 2021

Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.170

7 January 2021

Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.170

7 January 2021

Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.170

7 January 2021

A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.170

7 January 2021

Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: a population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.170

7 January 2021

Does the evidence support the use of mycophenolate mofetil therapeutic drug monitoring in clinical practice? A systematic review.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.170

7 January 2021

Therapeutic drug monitoring of mycophenolic acid

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.170

7 January 2021

Pharmacokinetics and Pharmacodynamics of Mycophenolic Acid After Enteric-Coated Mycophenolate Versus Mycophenolate Mofetil in Patients With Progressive IgA Nephritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.170

7 January 2021

Pharmacokinetics of mycophenolate mofetil for autoimmune disease in children

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.170

7 January 2021

Association between mycophenolic acid 12-h trough levels and clinical endpoints in patients with autoimmune disease on mycophenolate mofetil

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.170

7 January 2021

Pharmacokinetics of mycophenolate mofetil in patients with autoimmune diseases compared renal transplant recipients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.170

7 January 2021

Pharmacokinetics of mycophenolate sodium and comparison with the mofetil formulation in stable kidney transplant recipients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.170

7 January 2021

Long-term changes in mycophenolic acid exposure in combination with tacrolimus and corticosteroids are dose dependent and not reflected by trough plasma concentration: a prospective study in 100 de novo renal allograft recipients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.170

7 January 2021

Therapeutic drug monitoring of mycophenolic acid in renal transplant recipients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.170

7 January 2021

The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.170

7 January 2021

Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.170

7 January 2021

The weight of pharmacokinetic parameters for mycophenolic acid in prediction of rejection outcome: the receiver operating characteristic curve analysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.170

7 January 2021

A retrospective analysis of mycophenolic acid and cyclosporin concentrations with acute rejection in renal transplant recipients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.170

7 January 2021

The 1982 revised criteria for the classification of systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.170

7 January 2021

The classification of glomerulonephritis in systemic lupus erythematosus revisited

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.170

7 January 2021

Measurement of mycophenolic acid in plasma or serum by a commercial enzyme inhibition technique in comparison with a high performance liquid chromatography method

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.170

7 January 2021

Clinical utility of a new enzymatic assay for determination of mycophenolic acid in comparison with an optimized LC-MS/MS method.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.170

7 January 2021

The American College of Rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.170

7 January 2021

Prediction of creatinine clearance from serum creatinine

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.170

7 January 2021

Identifiers

DOI

10.1038/KI.2010.170

1 reference

12 November 2017

1 reference